Ultime notizie per PepGen (NASDAQ:PEPG) Azioni

PepGen

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

PepGen Inc

<p>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.88) by 34.09 percent.</p>


Earnings

Earnings Beats

News

SAVA

Cassava Sciences Q3 2024 GAAP EPS $(0.58) Beats $(0.88) Estimate

<p>Needham  analyst Bernie McTernan   reiterates Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and maintains $16 price target.</p>


Price Target

Reiteration

Analyst Ratings

SRAD

Needham Reiterates Buy on Sportradar Gr, Maintains $16 Price Target

<p>Burford Capital Limited, the leading global finance and asset management firm focused on law, has noted inaccurate media reporting and subsequent market reaction to an expected court filing last night by the U.S. Department of Justice ("DOJ") in the Petersen and Eton Park matters. The filing in the U.S. District Court for the Southern District of New York restates DOJ's position on a narrow question of law in relation to enforcement of judgments. The filing pertains to one motion filed in the Petersen and Eton Park matters as part of the overall, ongoing effort to enforce the judgment against the Argentine Republic. The filing does not reflect DOJ's taking any broader position on the overall case or the enforcement campaign; indeed, DOJ has previously taken the position that pursuing Argentina in the US courts for its breach of contract in this matter was appropriate, and DOJ has not made any filing at all on the pending appeal (and the time to do so has passed). In its filing, DOJ took the view that Argentina could not be required by a U.S. court to move property presently located in Argentina into the United States so it could there be attached for creditors under New York law, which is an unsettled legal issue. The DOJ view is not binding on the court and further briefing and proceedings will ensue. The Company will provide a further update on the Petersen and Eton Park matters during today's earnings call.</p>


Legal

Burford Capital Highlights Inaccurate Media Reports On DOJ Court Filing In Petersen, Eton Park Cases; Filing Focuses on Legal Enforcement Issue, Not Broader Case; DOJ States Argentina's Property Cannot Be Moved To U.S. For Creditor Attachment; The DOJ View Is Not Binding On The Court And Further Briefing And Proceedings Will Ensue

<p>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.84) by 7.14 percent.</p>


Guidance

TRML

Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded the rating for <strong>McKesson Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raised the price target from $531 to $688. McKesson shares closed at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded <strong>United States Cellular Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) from Market Perform to Outperform and announced a price target of $86. United States Cellular shares closed at $65.15 on Wednesday. <a href="https://www.benzinga.com/quote/USM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00b6e13513fb0001f03e9b/kristen-kluska">Cantor Fitzgerald analyst Kristen Kluska</a> upgraded the rating for <strong>Sarepta Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and boosted the price target from $152 to $167. Sarepta Therapeutics shares closed at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev upgraded <strong>Clearwater Analytics Holdings, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Neutral to Overweight and raised the price target from $23 to $33. Clearwater Analytics shares closed at $28.58 on Wednesday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Steven Cahall upgraded the rating for <strong>Sinclair, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) from Underweight to Equal-Weight and increased the price target from $13 to $19. Sinclair shares closed at $17.41 on Wednesday. <a href="https://www.benzinga.com/quote/SBGI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying MCK stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png" alt="" class="wp-image-635130" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom"> </a></strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></strong></li>
</ul>


Upgrades

Pre-Market Outlook

Markets

Trading Ideas

CWAN

SBGI

SRPT

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

<p>Keefe, Bruyette &amp; Woods  analyst Paul Johnson   upgrades TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) from Underperform to Market Perform and lowers the price target from $8 to $7.5.</p>


TPVG

Keefe, Bruyette & Woods Upgrades TriplePoint Venture Gwth to Market Perform, Lowers Price Target to $7.5

Biotech

Health Care

General

CARM

CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025

<p>Stephens &amp; Co.  analyst Jim Salera   reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $62 price target.</p>


PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $62 Price Target

WIIM

KVYO

Klaviyo shares are trading lower. The company reported Q3 financial results.

<p>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent.  The company reported quarterly sales of $3.38 million which missed the analyst consensus estimate of $5.47 million by 38.08 percent.  This is a 11.55 percent decrease over sales of $3.83 million the same period last year.</p>


CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate

MRNA

Moderna shares are trading higher after the company reported better-than-expected Q3 sales results.

<p>Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.92 by 33.7 percent.  The company reported quarterly sales of $249.114 million which missed the analyst consensus estimate of $393.893 million by 36.76 percent.  This is a 32.47 percent decrease over sales of $368.873 million the same period last year.</p>


Earnings Misses

Burford Capital Q3 2024 GAAP EPS $0.61 Misses $0.92 Estimate, Sales $249.114M Miss $393.893M Estimate

<p>Chicago Atlantic Real Estate Finance, Inc<em>.</em>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) <a href="https://www.globenewswire.com/en/news-release/2024/11/07/2976505/0/en/Chicago-Atlantic-Real-Estate-Finance-Announces-Third-Quarter-2024-Financial-Results.html">announced</a> strong third-quarter results for 2024. The company, a commercial mortgage real estate investment trust (REIT) specializing in cannabis-related assets, reported significant net income growth and expanding portfolio performance, underpinned by disciplined loan management.</p>
<h3 class="wp-block-heading"><strong>Key Financial Highlights for Q3 2024</strong></h3>
<ul>
<li><strong>Net Interest Income:</strong>&nbsp;$14.5 million, up from $13.2 million in Q2 2024 and a 9.1% increase from Q3 2023.</li>
<li><strong>Net Income:</strong>&nbsp;$11.2 million, or $0.56 per share, a 21.7% sequential increase and a 19% year-over-year increase.</li>
<li><strong>Distributable Earnings:</strong>&nbsp;$11.2 million, or $0.56 per share, reflecting a 12% quarterly increase and a 15% year-over-year rise.</li>
<li><strong>Book Value:</strong>&nbsp;$15.05 per share, up slightly from $14.92 in <a href="https://www.benzinga.com/markets/cannabis/24/08/40228072/cannabis-reit-chicago-atlantic-nets-9-2m-in-strong-q2-citing-regulatory-tailwinds">Q2 2024</a>, showing growth in shareholder equity.</li>
</ul>
<h3 class="wp-block-heading"><strong>Portfolio And Investment Activity</strong></h3>
<p>As of September 30, 2024, Chicago Atlantic's portfolio included<strong> $362.3 million in <a href="https://www.benzinga.com/markets/cannabis/24/10/41496393/chicago-atlantic-secures-bbb-rating-and-50m-loan-to-enhance-liquidity-in-cannabis-lending">loan principal </a>across 29 companies</strong>, with a real estate collateral coverage of 1.2x, slightly down from 1.3x in June. </p>
<p>The company originated $32.7 million in gross loans during Q3, including $24 million to new borrowers and $8.7 million to existing ones, with a weighted average yield to maturity of 18.3%. </p>
<p>After the quarter's close, Chicago Atlantic funded an additional $36.5 million, including a $25 million credit facility with an Illinois operator.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</em></strong></li>
</ul>
<p>"We have managed our portfolio and its maturities very well throughout 2024 with extensions, modifications, and refinancings, while improving credit quality and loan coverage,&#8221; stated co-CEO <strong><a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">Peter Sack</a></strong>. &#8220;A strong pipeline in both existing and new states with adult-use legislation keeps us well-positioned for the balance of the year and into 2025."</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">EXCLUSIVE: Weed Companies Will Be Treated Like Normal Businesses Once This Tax Provision Goes Away, Experts Say</a></strong></p>
<h3 class="wp-block-heading"><strong>Capital And Liquidity Management</strong></h3>
<p>During Q3, Chicago Atlantic increased its secured revolving credit facility to $110 million, with a drawdown of $54 million as of quarter-end, resulting in a leverage ratio of 18%. </p>
<p>In October, the company secured a $50 million unsecured term loan with a fixed interest rate of 9.0% and received an investment-grade BBB+ rating from Egan-Jones. This loan strengthens Chicago Atlantic's liquidity, leaving $94.5 million available under the facility and approximately $80 million in total liquidity as of early November.</p>
<p>The company also paid a quarterly dividend of $0.47 per share on October 15, reflecting its steady return to shareholders amid robust performance.</p>
<h3 class="wp-block-heading"><strong>REFI Stock Price Action</strong></h3>
<p>REFI shares closed Wednesday at <strong>$15.58</strong> per share gaining +0.33 during the trading session, which represents a 2.16% increase.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40607517/delivering-returns-as-the-cannabis-market-tanks-what-wall-st-wont-tell-you-about-ch">Delivering Returns As The Cannabis Market Tanks: What Wall St Won&#8217;t Tell You About Chicago Atlantic Real Estate&#8217;s Growth</a></strong></li>
</ul>
<p><em>COVER: AI Generated Image</em></p>


Cannabis

REFI

Chicago Atlantic Real Estate Net Income Increases 19% YoY, Expands Cannabis Loan Portfolio

<p>Vertical Research   upgrades Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) from Hold to Buy and announces $109 price target.</p>


Vertical Research Upgrades Intl Flavors & Fragrances to Buy, Announces $109 Price Target

<p>HC Wainwright &amp; Co.  analyst Kevin Dede   maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $15 to $17.</p>


Core Scientific, Inc. - Class A Common Stock

CORZ

HC Wainwright & Co. Maintains Buy on Core Scientific, Raises Price Target to $17

United States Cellular shares are trading higher after the company announced an agreement with AT&T to sell a portion of its retained spectrum licenses for $1.018 billion.

Dividends

CCOI

Cogent Communications Raises Dividend From $0.985 To $0.995

PRTH

Priority Technology Holdings shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Turning Point Brands shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its guidance.

<p><strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) released its Q3 earnings on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.01 in the last quarter, resulting in a 3.0% drop share price change the following day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Latest Earnings Reports from Competitors</h3>
<p>With Clear Channel Outdoor's earnings data now available, it's crucial to gauge how its competitors, including PubMatic, TechTarget, and National CineMedia, have been performing.</p>
<ul>
<li>PubMatic's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's projected EPS of $-0.02, resulting in a 950.0% increase.</li>
<li>TechTarget's earnings on August 08, 2024 exceeded market projections, revealing an EPS of $0.42 compared to the estimated EPS of $0.4, resulting in a 5.0% increase.</li>
<li>National CineMedia announced earnings on November 05, 2024, revealing results below market expectations. Despite the market's anticipation of an EPS of $-0.03, National CineMedia's actual EPS was $-0.04, resulting in a -33.33% decrease compared to expectations.</li>
</ul>
<h3>Competitors Quarterly Earnings and Stock Performance Analysis</h3>
<p>In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Study: Estimated vs. Actual Peer Revenues</h3>
<p>Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Clear Channel Outdoor Q3 Earnings Assessment

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on PEPG stock, giving a Buy rating yesterday. Joseph Schwartz has give...

Optimistic Outlook on PepGen's DMD Therapy Despite Initial Data: Analyst Reiterates Buy Rating

REGENXBIO releases new data on DMD drug ahead of earnings

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>PepGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pepg-stock-quote/"><strong>PEPG</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>PepGen reported earnings per share of -87 cents. This was below the analyst estimate for EPS of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/pepg-stock-earnings-pepgen-for-q2-of-2024/">PEPG Stock Earnings: PepGen Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PEPG Stock Earnings: PepGen Misses EPS for Q2 2024

PepGen GAAP EPS of -$0.87

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kura Oncology (KURA – Research Report), Tenaya Thera...

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Tenaya Therapeutics (TNYA) and PepGen Inc. (PEPG)

Dyne stock tumbles 31% amid drug updates, management changes

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

PepGen Inc. ( ($PEPG) ) has shared an announcement. Christopher Ashton, Ph.D., has announced his intention to retire from the Board of Directors of...

PepGen Inc. Board Reshuffles as Ashton Plans Retirement

Avidity gets FDA partial clinical hold lifted on DM1 drug candidate

AAPL

ACHC

ADBE

ADPT

AMZN

AVGO

BBIO

BMRN

CAPR

CPRX

DASH

DDOG

DLTR

EWTX

FDMT

FERG

INBX

KURA

LBPH

MSCLF

MSFT

NAMS

NFLX

ORIC

PEPG

PHVS

RGNX

RHHBY

ROIV

RPRX

SLDB

TMUS

TNYA

TRDA

TRVI

TTWO

VKTX

VRTX

WDAY

Press Releases

PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

PepGen to Participate in Upcoming Investor Conferences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

PepGen

Notizie

Ultime notizie per PepGen (NASDAQ:PEPG) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO